Form 4: Citius Oncology CFO Boosts Equity Holdings

Citius Oncology's Chief Financial Officer, Jaime Bartushak, reported significant equity acquisitions, including restricted stock and stock options, signaling increased insider ownership.

Summary

• Jaime Bartushak, Chief Financial Officer of Citius Oncology, Inc. (CTOR), reported the acquisition of 825,000 shares of common stock through restricted stock awards on September 19, 2025.
• These restricted shares will vest in three substantially equal installments on the first, second, and third anniversaries of the grant date, contingent on continuous service.
• Bartushak also holds 400,000 stock options granted on December 12, 2024, with an exercise price of $1.07, expiring on December 12, 2034.
• These 400,000 options vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the grant date, subject to continuous service.
• Additionally, Bartushak holds 1,400,000 stock options granted on July 5, 2023, with an exercise price of $2.15, expiring on July 5, 2033.
• These 1,400,000 options vest over three years, beginning July 5, 2023, with 1/36th vesting monthly for the first year, and 1/3 vesting on each of the second and third anniversaries of the grant date, subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Increased insider ownership, especially by a CFO, generally signals confidence in the company's future prospects and aligns management's interests with shareholders. However, it's a compensation event rather than a direct investment, and the value is subject to future performance and vesting conditions.

Positives

• Increased insider ownership by a key executive (CFO) aligns management's interests with those of shareholders, potentially indicating confidence in the company's future.
• The equity grants serve as long-term incentives, encouraging the CFO to contribute to sustained company performance over several years.

Negatives

• The restricted stock and options are subject to vesting conditions, meaning the executive does not have immediate, unrestricted ownership or liquidity.
• The value of the stock options is dependent on the future stock price exceeding the exercise price, introducing market risk.

Risks

• The vesting of restricted stock and options is contingent upon the Reporting Person's continuous service to Citius Oncology, Inc. or a Related Entity, posing a risk of forfeiture if service terminates.
• The ultimate value realized from the stock options is subject to the volatility of Citius Oncology's stock price, which may not exceed the exercise prices.
• The company's performance and market conditions could negatively impact the value of these equity awards.

Future Outlook

The equity grants to the Chief Financial Officer are structured as long-term incentives, aligning the executive's financial interests with the company's future performance over the next one to three years, subject to continuous service and successful execution of company strategy.

Industry Context

Executive compensation packages in the biotechnology and pharmaceutical sectors frequently include significant equity components, such as restricted stock and stock options, to attract and retain talent, and to align executive incentives with long-term shareholder value creation. These grants are typical for senior leadership roles.

Comparison to Industry Standards

• The structure of these equity grants, involving multi-year vesting schedules for both restricted stock and stock options, is a common practice in the biotechnology industry for executive compensation.
• The use of performance-based or time-based vesting, contingent on continuous service, is standard for aligning executive incentives with company longevity and shareholder returns, similar to practices observed at comparable emerging biotech firms.

Stakeholder Impact

• Shareholders: The increased equity ownership by the CFO aligns management's long-term interests with those of shareholders, potentially fostering greater commitment to increasing shareholder value.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its leadership team.

Next Steps

• The restricted stock awards will vest in three substantially equal installments on the first, second, and third anniversaries of the September 19, 2025 grant date.
• The 400,000 stock options will vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the December 12, 2024 grant date.
• The 1,400,000 stock options will continue to vest monthly for the first year from July 5, 2023, and then 1/3 on each of the second and third anniversaries of the July 5, 2023 grant date.

Key Dates

Keywords

Citius Oncology, CTOR, Form 4, Insider Ownership, Stock Options, Restricted Stock, Executive Compensation, Jaime Bartushak, CFO, Equity Grant